{
  "id": 8595220,
  "title": "Durable suppression of viremia by lipid nanoparticle-formulated RNA encoding for a highly potent HIV-1 neutralizing antibody",
  "url": "https://urgent.news/2026/09/19/durable-suppression-of-viremia-by-lipid-nanoparticle-formulated-rna",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-19T00:00:00.000Z",
  "source": {
    "name": "bioRxiv",
    "slug": "biorxiv",
    "url": "https://www.biorxiv.org/content/10.64898/2026.09.17.752120v1?rss=1"
  },
  "original_language": "en",
  "account": "A groundbreaking study has demonstrated the potential of lipid nanoparticle-formulated RNA to effectively suppress HIV-1 infection. The research focused on encoding the highly potent HIV-1 neutralizing antibody, 1-18-LS, on RNA, which was then delivered via lipid nanoparticles (LNPs).\n\nHuman neonatal Fc receptor-transgenic mice injected with 30 micrograms of RNA-LNP saw an average peak serum concentration of 1,061 micrograms per milliliter of the 1-18-LS RibobNAb. Remarkably, weekly 30 microgram RNA-LNP doses maintained higher trough levels of the bNAb compared to 500 microgram protein injections.\n\nThe study found that RNA-LNP-mediated 1-18-LS RibobNAb monotherapy in HIV-1YU2-infected humanized mice led to durable HIV-1 suppression without any emerging viral escape. Furthermore, the treatment fully controlled infection after interruption of antiretroviral therapy in mice infected with different patient-derived polyclonal HIV-1 isolates.\n\nThis innovative approach offers a promising proof-of-principle for RNA-mediated bNAb immunotherapy in the fight against HIV-1 infection.",
  "summary": "Recombinant broadly neutralizing antibodies (bNAbs) are promising tools to treat and prevent HIV-1 infection but are associated with manufacturing challenges. To overcome this limitation, we encoded the potent bNAb 1-18-LS on RNA (1-18-LS RibobNAb) for delivery via lipid nanoparticles (LNPs). Indicating high in vivo antibody expression, a 30 ug RNA-LNP intravenous injection resulted in an average…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}